Pluristem Therapeutics (PSTI) Downgraded to Strong Sell at ValuEngine
ValuEngine cut shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a strong sell rating in a research note published on Wednesday.
Several other brokerages have also recently commented on PSTI. Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the stock a buy rating in a research report on Thursday, October 26th. Zacks Investment Research cut Pluristem Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. Seaport Global Securities reaffirmed a buy rating and issued a $5.00 target price on shares of Pluristem Therapeutics in a research report on Friday, October 6th. Finally, HC Wainwright reaffirmed a buy rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $3.83.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at $1.45 on Wednesday. The stock has a market cap of $152.55, a price-to-earnings ratio of -4.53 and a beta of 0.09. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $2.12.
Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). equities research analysts forecast that Pluristem Therapeutics will post -0.34 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC lifted its holdings in shares of Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 34,742 shares during the period. Psagot Investment House Ltd. lifted its holdings in shares of Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 122,347 shares during the period. Finally, Heritage Investors Management Corp bought a new position in shares of Pluristem Therapeutics during the third quarter valued at $113,000. 4.31% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://theolympiareport.com/2017/12/24/pluristem-therapeutics-psti-downgraded-to-strong-sell-at-valuengine.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.